Summary
Plasma samples and biopsies of vaginal tissue were obtained from 23 healthy women undergoing operative sterilization, 1 to 6 h after a single oral dose of ketoconazole 200 mg. Drug concentrations in plasma and tissue, were measured by a specific gas chromatographic method. The vaginal tissue concentration averaged 2.4 times less than the corresponding plasma levels. Equilibrium between tissue, and plasma was established within 1 h after dosing, when vaginal tissue levels exceeded 1 µg/g. Ketoconazole concentrations decayed monoexponentially over the time interval studied (1–6 h), with the similar half-lives of 1.2 and 1.4 h in plasma and tissue, respectively. Following an oral 200 mg dose, a tissue concentration not less than 0.01 µg/ml was maintained over a 12 h period. This concentration has been shown to prevent outgrowth of the invasive (pseudo) mycelial form ofCandida albicans. Hence, a b.i.d. or t.i.d. dosage schedule of ketoconazole in vaginal candidosis would give continuously effective levels at the site of infection. Ketoconazole concentrations in vaginal fluid are thought to be much higher than in the tissue because of ion-trapping. The present data may explain the efficacy of oral ketoconazole in the treatment of vaginal candidosis.
Similar content being viewed by others
References
Bisschop M, Merkus J, Scheygrond H, Van Cutsem J, van de Kuy A (1979) Treatment of vaginal candidiasis with ketoconazole, a new, orally active, antimycotic. Eur J Obstet Gynecol Reprod Biol 9: 253–259
Borgers M (1980) Mechanism of action of antifungal drugs, with reference to the imidazole derivatives. Rev Infect Dis 2: 520–534
Creatsas G, Zissis N, Lolis D (1980) Ketoconazole, a new antifungal agent, in vaginal candidiasis. Curr Ther Res 28: 121–126
Gascoigne E, Barton G, Michiels M, Meuldermans W, Heykants J (1981) The kinetics of ketoconazole in animals and man. Clin Res Rev 1: 177–187
Heel R (1982) Pharmacokinetic properties. In: Levine H (ed) Ketoconazole in the management of fungal disease. ADIS Press, New York
Heel R (1982) Vaginal Candidosis. In: Levine H (ed) Ketoconazole in the management of fungal disease. ADIS Press, New York
Heeres J, Backx L, Mostmans J, Van Cutsem J (1979) Antimycotic imidazoles. Part 4. Synthesis and antifungal activity of ketoconazole, a new potent orally active broad-spectrum agent. J Med Chem 22: 1003–1005
Rakoff A, Feo L, Goldstein L (1944) The biologic characteristics of the normal vagina. Am J Obstet Gynecol 47: 467–494
Schanker L (1962) Passage of drugs across body membranes. Pharmacol Rev 14: 501–530
Symoens J, Moens M, Dom J, Scheygrond H, Dony J, Schuermans V, Legendre R, Finestine N (1980) An evaluation of two years of clinical experience with ketoconazole. Rev Infect Dis 2: 674–687
Symoens J, Cauwenbergh G (1981) Treatment of systemic mycoses with miconazole and ketoconazole. Mykosen 24 [Suppl 1]: 70–78
Thienpont D, Van Cutsem J, Borgers M (1980) Ketoconazole in experimental candidosis. Rev Infect Dis 2: 570–576
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Heykants, J.J.P., Woestenborghs, R.J.H., Bisschop, M.P.J.M. et al. Distribution of oral ketoconazole to vaginal tissue. Eur J Clin Pharmacol 23, 331–333 (1982). https://doi.org/10.1007/BF00613615
Received:
Accepted:
Issue Date:
DOI: https://doi.org/10.1007/BF00613615